This project aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia. We have already conducted 5 rounds of serological survey. According to data collected in October 2021, 83% of St. Petersburg residents have SARS-CoV-2 antibodies.
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
Organizer:
Institute for Interdisciplinary Health Research (IIHR)
Project start date:
2020-05-05
Project News
83% of petersburgers have coronavirus antibodies
15.11.2021
According to the results of the new stage of a serological survey, more than 80% of adults in St. Petersburg have antibodies to SARS-CoV-2. Repeat infections (confirmed by PCR tests) are relatively rare events-under 3%. In order for the active phase of the epidemic to end, as many citizens as possible must have immune protection.
Публикации проекта
COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data
Year of publication:
This study summarises results from four consecutive serological surveys conducted between May 2020 and April 2021 at St. Petersburg, Russia and combines them with other SARS-CoV-2 surveillance data.
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
Publication URL:
Тип издания:
Журнал
Year of publication:
This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias.
Evaluation of the performance of SARS-CoV-2 antibody assays for a longitudinal populationbased study of COVID-19 spread in St. Petersburg, Russia
Publication URL:
Тип издания:
Журнал
Year of publication:
This study summarizes an evaluation of antibody tests used in a serological study of SARS-CoV-2 in Saint Petersburg, Russia. Researches validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS-CoV-2 immunoglobulin G (IgG), enzyme linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA SARS-CoV-2-IgG-EIA-BEST.